GlassScriptPhysician profile
Amy D Harper
NPI 1700289741
$3,937.18
in general payments reported to CMS, 2019-2025
25 companies · $686 in 2025
The $686 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $547 · 2022: $1,056 · 2023: $880 · 2024: $769 · 2025: $686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,334.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $626.43 | 2021-2025 | |
| Genzyme Corporation | $468.45 | 2023-2024 | |
| Glaxosmithkline, LLC. | $451.08 | 2021-2023 | Arexvy, Nucala |
| Dexcom, INC. | $380.66 | 2021-2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Novo Nordisk INC | $310.31 | 2021-2023 | Wegovy |
| Inspire Medical Systems, INC. | $272.04 | 2024-2025 | Inspire |
| Mylan Specialty L.P. | $124.99 | 2024 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $121.86 | 2022 | |
| Kyowa Kirin, INC. | $121.86 | 2025 | |
| Amgen INC. | $119.60 | 2021-2023 | Repatha, Prolia, Evenity |
| Gilead Sciences, INC. | $116.15 | 2025 | Epclusa |
| Axsome Therapeutics, INC. | $112.12 | 2025 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $112.08 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $90.93 | 2024 | Rexulti |
| Jazz Pharmaceuticals INC. | $80.48 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $67.26 | 2023 | |
| Vapotherm INC | $66.17 | 2023 | Vapotherm |
| Biogen, INC. | $61.43 | 2024 | |
| Coloplast Corp | $56.33 | 2023 | Titan |
| Takeda Pharmaceuticals U.S.A., INC. | $36.20 | 2021-2022 | |
| Abbott Laboratories | $33.87 | 2023 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $33.15 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.48 | 2021 | |
| Antares Pharma, INC. | $24.93 | 2021-2023 | Xyosted, Nocdurna, Tlando |
| Evofem Biosciences, INC. | $17.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Harper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.